{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-043944","form_type":"8-K","ticker":"ELDN","cik":"0001404281","company_name":"Eledon Pharmaceuticals, Inc.","filed_at":"2021-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:17.967322+00:00","generated_at":"2026-06-29T12:39:34.190920+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Eledon posts Q2 net loss $7.4M; advances AT-1501 into kidney transplant, IgAN trials","bullets":["Net loss $7.4M ($0.50/share) vs $2.6M loss in Q2 2020; R&D spend rose to $4.2M from $0.8M.","Cash $101.1M as of June 30, 2021; company expects to fund operations into 2023.","Health Canada cleared clinical trial of AT-1501 for kidney transplant rejection; initiation in Q4, data late 2022.","FDA agreed on preclinical renal transplant study of AT-1501 monotherapy in 4 non-human primates; data mid-2022.","Plans to develop AT-1501 for IgA nephropathy (IgAN), Phase 2 trial expected to start in Q4 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-043944","json":"https://secwatch.observer/filing/0001564590-21-043944.json","markdown":"https://secwatch.observer/filing/0001564590-21-043944.md","text":"https://secwatch.observer/filing/0001564590-21-043944.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1404281/000156459021043944/0001564590-21-043944-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1404281/000156459021043944/eldn-8k_20210812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T12:39:34.190920+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}